Glycanostics
Glycanostics is a biotechnology company that provides a test for the diagnostics of prostate cancer.
Operating in biotechnology, health care, health diagnostics based in European Union (EU), Europe, Middle East, and Africa (EMEA), Glycanostics was founded in 2017.
Within the biotechnology, health care, health diagnostics space, the company focuses on its core offering rather than a broad product line.
The company is recorded as being based in European Union (EU), Europe, Middle East, and Africa (EMEA).
The company is listed at the Grant stage of development.
Its team size is recorded as c_00011_00050 employees.
Public records show total funding of about $2M.
| Sector | Biotechnology, Health Care, Health Diagnostics |
|---|---|
| Headquarters | European Union (EU), Europe, Middle East, and Africa (EMEA) |
| Founded | 2017 |
| Employees | c_00011_00050 |
| Stage | grant |
| Total funding | $1,987,387 |
Website: glycanostics.com
Browse related
Emails and contact routes are reserved for registered members.
Create a free account
Create a free account